Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

20081,049 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 373, Issue 9662, pp. 473-481

Field-Weighted Citation Impact: 64.29